Merck Receives Breakthrough Therapy Designation from U.S.FDA for KEYTRUDA(R) (pembrolizumab) in Advanced Colorectal Cancer
November 02, 2015 at 08:10 AM EST
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) ...